PARAGON MEDICAL
Acquired by
AMERICAN SECURITIES
PARAGON MEDICAL acquired by AMERICAN SECURITIES
Target
PARAGON MEDICAL
Acquirer
AMERICAN SECURITIES
Context
The divestiture of the Life Sciences division by NN inc. (Paragon Medical) to American Securities represents a pivotal structural transformation for both organizations. For the seller, the transaction provides a necessary capital infusion to significantly reduce corporate debt and reposition its remaining industrial platform toward power and mobile solutions. The strategic rationale for the move centers on the acquirer’s objective to combine the division’s high-precision surgical capabilities with its existing portfolio company, MW Industries, thereby creating a comprehensive engineering powerhouse for specialized fasteners and medical components. By adding this technical specialist to its healthcare portfolio, American Securities seeks to capitalize on the industrial synergies existing between its various holdings in precision manufacturing, notably MW Industries. This capital allocation is designed to capture the resilient, non-discretionary demand inherent in the orthopedic and surgical instrumentation sectors during a period of macroeconomic instability. The financial sponsorship provides the target with the strategic resources required to accelerate innovation in minimally invasive technologies without the constraints of its previous debt-laden corporate structure. Ultimately, this portfolio maneuver solidifies the platform's standing as a primary enabler of critical component supply in global healthcare and industrial markets.
PARAGON MEDICAL, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a level LOGIN the 12.8x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Paragon Medical functions as a premier technology-driven organization specializing in the design, engineering, and manufacturing of critical medical components and surgical instruments. The entity’s business model is built on an industrialized framework as a contract development and manufacturing organization (CDMO), providing technical operational depth to global medical device leaders. Its value proposition is anchored in high-precision micro-machining and specialized metallurgy for orthopedic implants, robotic surgical tools, and drug delivery systems. Strategically, the firm focuses on being a mission-critical partner in the healthcare supply chain, offering end-to-end solutions from prototyping to high-volume commercial production. By maintaining a diverse portfolio of single-use instruments and implantable hardware, the organization ensures the structural reliability of advanced therapeutic procedures. The entity prioritizes manufacturing excellence and technical agility to facilitate the rapid scaling of medical innovations in a highly regulated landscape.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with PARAGON MEDICAL
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 11/2023 | AMETEK | PARAGON MEDICAL | UNITED STATES | Medical Devices | Paragon Medical has been acquired by AMETEK. This successful acquisition represents a significant tactical expansion of the group’s capabilities within the high-growth healthcare technology sector. Paragon Medical will join AMETEK’s Electromechanical division, creating a more diversified portfolio of mission-critical medical solutions. The strategic rationale hinges on the fusion of Paragon Medical’s leadership in surgical instrumentation and implantable components with AMETEK’s global reach and industrialized operating model. This operation will enable AMETEK to reinforce its ability to address the increasing demand for advanced orthopedic and robotic surgical tools driven by aging global demographics and the shift toward minimally invasive procedures. |
| 05/2018 | NN | PARAGON MEDICAL | UNITED STATES | Medical Devices | The integration of Paragon Medical into the NN, Inc. life sciences portfolio represents a definitive shift in the group's overarching corporate strategy. By absorbing Paragon Medical, NN, Inc. significantly enhances its technical proficiencies and diversifies its finished device offerings, moving beyond traditional industrial components into highly regulated healthcare markets. The strategic rationale for the transaction centers on the fusion of Paragon Medical’s niche leadership in orthopedic instrumentation with NN, Inc.’s global manufacturing scale and materials science depth. This operation allows NN, Inc. to build a more balanced business model, mitigating exposure to volatile industrial cycles by capturing non-discretionary demand in the surgical hardware space. The partnership acts as a catalyst for geographic and technical expansion, providing the strategic resources required to scale Paragon Medical's specialized capabilities across an international platform. Ultimately, the merger consolidates a high-performance life sciences division, positioning the organization as a primary enabler of medical device innovation and precision manufacturing on a global scale. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.